All In Biotech

Drug Trial Radar · NCT07133633

A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 315 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

315

Planned (sponsor's estimate)

Start

Sep 26, 2025

Primary completion

Mar 29, 2027

Study completion Feb 5, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Aug 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat radiographic axial spondyloarthritis (r-axSpA). R-axSpA is a type of arthritis that causes pain, stiffness, and inflammation (swelling) in the spine and joints in the pelvis (hip bone). Radiographic means the damage it causes can be seen on X-rays. This study will help find out if a study medicine called tulisokibart can treat symptoms of r-axSpA. Researchers will look at different doses of tulisokibart. Researchers want to know if at least one of the study doses of tulisokibart works better than a placebo to improve r-axSpA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Conditions

  • Radiographic Axial Spondyloarthritis

Interventions

  • TulisokibartDrug

    Subcutaneous (SC) administration

  • PlaceboDrug

    SC administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Assessment of Spondyloarthritis International Society (ASAS) 40 Response at Week 16Time frame: Week 16

Locations

108 sites in 14 countries. Site status is shown where the registry gives one.

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler ( Site 0036)

    Chandler, Arizona

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff ( Site 0021)

    Flagstaff, Arizona

  • Arizona Arthritis & Rheumatology Associates, P.C. - Gilbert ( Site 0022)

    Gilbert, Arizona

  • AARA Arizona Arthritis & Rheumatology Associates, P.C. - Glendale ( Site 0056)

    Glendale, Arizona

  • Arizona Arthritis & Rheumatology Associates, P.C. - Tucson ( Site 0025)

    Tucson, Arizona

  • TriWest Research Associates - Chula Vista ( Site 0013)

    Chula Vista, California

  • Providence Medical Foundation ( Site 0049)

    Fullerton, California

  • Newport Huntington Medical Group ( Site 0005)

    Huntington Beach, California

  • Cohen Medical Centers ( Site 0034)

    Thousand Oaks, California

  • Inland Rheumatology Clinical Trials, Inc. ( Site 0002)

    Upland, California

  • Denver Arthritis Clinic ( Site 0064)

    Denver, Colorado

  • Arthritis and Rheumatic Disease Specialties ( Site 0016)

    Aventura, Florida

  • Bay Area Arthritis and Osteoporosis ( Site 0041)

    Brandon, Florida

  • GNP Research - Hollywood ( Site 0020)

    Cooper City, Florida

  • Innovation Medical Research Center ( Site 0012)

    Palmetto Bay, Florida

  • Chicago Arthritis & Regenerative Medicine ( Site 0042)

    Chicago, Illinois

  • Willow Rheumatology and Wellness, PLLC ( Site 0035)

    Willowbrook, Illinois

  • John Hopkins University ( Site 0052)

    Baltimore, Maryland

  • Arthritis and Rheumatism Associates - Rockville ( Site 0019)

    Rockville, Maryland

  • Kansas City Physician Partners ( Site 0027)

    Kansas City, Missouri

  • Velocity Clinical Research - West County Rheumatology, St. Louis ( Site 0038)

    St Louis, Missouri

  • Logan Health Rheumatology ( Site 0015)

    Kalispell, Montana

  • Physician Research Collaboration, LLC ( Site 0057)

    Lincoln, Nebraska

  • Inspire Santa Fe Medical Group ( Site 0011)

    Santa Fe, New Mexico

  • Joseph S. and Diane H. Steinberg Ambulatory Care Center ( Site 0063)

    Brooklyn, New York

  • Oregon Health & Science University ( Site 0059)

    Portland, Oregon

  • Altoona Center for Clinical Research ( Site 0004)

    Duncansville, Pennsylvania

  • Perelman Center for Advanced Medicine ( Site 0060)

    Philadelphia, Pennsylvania

  • AARA Clinical Research - Murfreesboro Medical Clinic ( Site 0029)

    Murfreesboro, Tennessee

  • Rheumatology Associates ( Site 0055)

    Arlington, Texas

  • Arthritis Care of Texas ( Site 0048)

    Corpus Christi, Texas

  • Lone Star Arthritis & Rheumatology Associates, P.C. ( Site 0028)

    Fort Worth, Texas

  • Provecta Research Network LLC ( Site 0054)

    Houston, Texas

  • The University of Texas Health Science Center at Houston ( Site 0065)

    Houston, Texas

  • AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Irving ( Site 0032)

    Irving, Texas

  • Epic Medical Research ( Site 0061)

    Red Oak, Texas

  • Advanced Rheumatology of Houston ( Site 0001)

    The Woodlands, Texas

  • DM Clinical Research - TRA ( Site 0010)

    Tomball, Texas

  • IBPClin - Instituto Brasil de Pesquisa Clínica ( Site 1994)

    Rio de Janeiro, Brazil

  • Centro de Pesquisas Clínicas do Hospital das Clínicas de São Paulo ( Site 1992)

    São Paulo, Brazil

Showing 40 of 108 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.